Oral Immune System Plasticity in Chronic HIV Infection Under Treatment and Oral Co-Infections (R01)

Post Date

March 17th 2016

Application Due Date

July 25th 2016

Funding Opportunity Number

RFA-DE-17-006

CFDA Number(s)

93.121

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $1100000

• Award Range:

  $None - $None

Grant Description

This Funding Opportunity Announcement (FOA) solicits research projects that study the mechanisms of oral immune system plasticity relevant to chronic HIV infection and oral coinfections.In this context, we encourage studies on reversal of immune activation, residual inflammation, immune reconstitution inflammatory syndrome (IRIS), and microbial and by-product translocation.These conditions occur in persons chronically infected with HIV who are treated with combination antiretroviral therapy (cART) and who also experience oral opportunistic infections.The ultimate goals of this FOA are: 1) to gain knowledge regarding the pathogenesis and persistence of these oral conditions; and 2) to guide the development of novel oral immune modulatory therapies that will aid in re-building the oral immune system to reverse these diseases, mitigate their progression, prevent their occurrence, and eliminate persistence of residual HIV and other oral pathogens in reservoirs.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-DE-17-006.html